Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) obtained marketing authorization for botulinum toxin type A injection from China's state drug administrator.
The injection is intended for treating cervical dystonia, according to a Wednesday filing with the Shanghai bourse.